NCT04583800Recruiting
Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes
Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes : Longitudinal Cohort Study of Immuno-inflammation, Cardiac Energetics and Cognition.PreciDIAB-HEART&BRAIN
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
Type 2 diabetes is a risk factor of heart failure and cognitive decline. Heart failure at its early stage is often silent. At present, primary prevention for heart failure is not available. Our aim is to identify diabetic patients at risk of heart failure in order to develop personalized preventive strategies. Type 2 diabetes is vascular and metabolic risk factor for cognitive decline though a direct lesional effect but also through an interaction with underlying neurodegenerative lesions. Our aim is to identify diabetic patients at risk of cognitive decline in order to develop personalized preventive strategies
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 28 Sept 2020
- Start date
- 22 Jun 2021
- Primary completion date
- Jun 2026
- Lead sponsor
- University Hospital, Lille
- Diseases
- Heart failure, Stroke, Type 2 diabetes
- NCT number
- NCT04583800
What you commit to
- Study type: Observational
- Planned participants: 600
- From 22 Jun 2021 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with dementia
- Patient with at least one of the criteria for heart failure ≥stade B
Who the study is looking for
- Adults
- Persons able to understand and object to the information provided.
- Type 2 diabetic patient free of heart failure ≥stade B
- Patient affiliated with a social security scheme.
- Patient agreeing to sign the informed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Roger Salengro, CHU Lille Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.